Context Therapeutics
CNTX
22 hedge funds and large institutions have $723K invested in Context Therapeutics in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 5 closing their positions.
8% less funds holding
Funds holding: 24 → 22 (-2)
16.26% less ownership
Funds ownership: 24.32% → 8.06% (-16%)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
72% less capital invested
Capital invested by funds: $2.55M → $723K (-$1.82M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$22.1K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$18.6K |
| 3 |
SSWM
Sheets Smith Wealth Management
Winston-Salem,
North Carolina
|
+$15.1K |
| 4 |
Two Sigma Advisers
New York
|
+$12.3K |
| 5 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
+$8.06K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$745K |
| 2 |
AAA
Affinity Asset Advisors
New York
|
-$584K |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$186K |
| 4 |
Renaissance Technologies
New York
|
-$65.2K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$51K |
CNTX Hedge Fund Activity: Q1 2023 in Review
22 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Context Therapeutics (CNTX) for Q1 2023, worth a combined $723K — down 72% from $2.55M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CNTX and 4 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 3 added.
The largest buyer was Two Sigma Investments, adding an estimated $22.1K. The largest seller was AIGH Capital Management, exiting entirely with an estimated $745K sold.
- 22 institutional investors held Context Therapeutics (CNTX) as of Q1 2023, down from 24 in Q4 2022.
- Funds reported $723K of Context Therapeutics stock for Q1 2023, down 72% quarter-over-quarter.
- 4 funds opened new Context Therapeutics positions in Q1 2023 and 5 closed out, a net change of -1 holder.
- The largest Context Therapeutics buyer in Q1 2023 was Two Sigma Investments, an estimated $22.1K added.
- The largest Context Therapeutics seller in Q1 2023 was AIGH Capital Management, an estimated $745K sold.
Based on aggregated 13F filings for Q1 2023.